| European Case Law Identifier: | ECLI:EP:BA:2005:T002004.20050316 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 16 March 2005 | ||||||||
| Case number: | T 0020/04 | ||||||||
| Application number: | 94919120.9 | ||||||||
| IPC class: | C12N 15/12 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Purified mammalian Flt3 ligands and agonists and antagonists thereof | ||||||||
| Applicant name: | SCHERING CORPORATION, et al | ||||||||
| Opponent name: | Immunex Corporation | ||||||||
| Board: | 3.3.08 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Main request: extension of the protection (yes) Auxiliary request 1: entitlement to the earliest priority date (yes) Novelty (yes) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t040020eu1.html
Date retrieved: 17 May 2021